Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to determine whether the combination of onartuzumab + erlotinib is superior (in terms of OS) to placebo + erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic−positive NSCLC.
Inclusion criteria
- MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER
- (NSCLC)